VistaGen Therapeutics to Present at 9th Annual LD Micro Main Event - Yahoo Finance

Submitted by Anonymous (not verified) on Wed, 11/30/2016 - 12:14

VistaGen Therapeutics to Present at 9th Annual LD Micro Main EventYahoo FinanceAV-101 (4-CI-KYN) is an orally available CNS prodrug candidate, currently in Phase 2 development, initially for the adjunctive treatment of MDD in patients with an inadequate response to standard FDA-approved antidepressants. AV-101 also has broad ...and more »